BR112019012776A2 - novas composições de canabinoide e métodos de uso - Google Patents

novas composições de canabinoide e métodos de uso Download PDF

Info

Publication number
BR112019012776A2
BR112019012776A2 BR112019012776-3A BR112019012776A BR112019012776A2 BR 112019012776 A2 BR112019012776 A2 BR 112019012776A2 BR 112019012776 A BR112019012776 A BR 112019012776A BR 112019012776 A2 BR112019012776 A2 BR 112019012776A2
Authority
BR
Brazil
Prior art keywords
cbd
fact
day
thc
composition
Prior art date
Application number
BR112019012776-3A
Other languages
English (en)
Portuguese (pt)
Inventor
Jacobson Catherine
Joshua Eades Caleb
Original Assignee
Tilray, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tilray, Inc. filed Critical Tilray, Inc.
Publication of BR112019012776A2 publication Critical patent/BR112019012776A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
BR112019012776-3A 2016-12-20 2017-12-20 novas composições de canabinoide e métodos de uso BR112019012776A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662436861P 2016-12-20 2016-12-20
US62/436,861 2016-12-20
PCT/IB2017/001683 WO2018115962A1 (en) 2016-12-20 2017-12-20 Novel cannabinoid compositions and methods of treating pediatric epilepsy

Publications (1)

Publication Number Publication Date
BR112019012776A2 true BR112019012776A2 (pt) 2019-12-10

Family

ID=61028091

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019012776-3A BR112019012776A2 (pt) 2016-12-20 2017-12-20 novas composições de canabinoide e métodos de uso

Country Status (12)

Country Link
US (1) US20200215022A1 (enExample)
EP (1) EP3558297A1 (enExample)
JP (2) JP2020514282A (enExample)
KR (1) KR20190099221A (enExample)
AU (1) AU2017381587A1 (enExample)
BR (1) BR112019012776A2 (enExample)
CA (1) CA3046320A1 (enExample)
CL (1) CL2019001668A1 (enExample)
CO (1) CO2019006911A2 (enExample)
MX (1) MX2019007496A (enExample)
PE (1) PE20200338A1 (enExample)
WO (1) WO2018115962A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
IL261132A (en) * 2018-08-13 2018-11-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
GB2580653A (en) * 2019-01-21 2020-07-29 Gw Res Ltd Use of cannabinoids in the treatment of comorbidities associated with epilepsy
EP3931330A4 (en) 2019-02-25 2023-03-15 Ginkgo Bioworks, Inc. BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS
US11759447B1 (en) 2019-06-26 2023-09-19 RCR BioPharma Compound and method for treating diseases and disorders
GB2598922A (en) * 2020-09-18 2022-03-23 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
CA3217137A1 (en) 2021-04-29 2022-11-03 Christopher Adair Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
WO2023047308A1 (en) * 2021-09-22 2023-03-30 Avicanna Inc. Methods for reducing or eliminating incidence of seizures and sudden unexpected death in epilepsy
JP2025512495A (ja) 2022-04-12 2025-04-17 シャッケルフォード・ファーマ・インコーポレーテッド 発作性障害の治療

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298284A3 (en) * 2001-02-14 2013-12-18 GW Pharma Limited Mucoadhesive pharmaceutical formulations
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
MX395015B (es) * 2014-12-12 2025-03-24 Ojai Energetics Pbc Composiciones microencapsuladas de cannabinoides
EP3265081A4 (en) * 2015-03-02 2018-11-21 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
US10555906B2 (en) * 2016-02-11 2020-02-11 Gelpell Ag Oral solid cannabinoid formulations, methods for producing and using thereof

Also Published As

Publication number Publication date
MX2019007496A (es) 2019-10-30
CO2019006911A2 (es) 2019-08-30
JP2023001138A (ja) 2023-01-04
EP3558297A1 (en) 2019-10-30
US20200215022A1 (en) 2020-07-09
CA3046320A1 (en) 2018-06-28
PE20200338A1 (es) 2020-02-14
WO2018115962A1 (en) 2018-06-28
JP2020514282A (ja) 2020-05-21
CL2019001668A1 (es) 2019-09-06
KR20190099221A (ko) 2019-08-26
AU2017381587A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
BR112019012776A2 (pt) novas composições de canabinoide e métodos de uso
US20230364052A1 (en) Composition and method for treating autism
US10660872B2 (en) Methods for treatment of cognitive decline
BR112019026877A2 (pt) composições para distúrbios do sono e tratamentos do mesmo
BR112018005423B1 (pt) Composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso
BR112018069860A2 (pt) composição fitoderivada que compreende pelo menos um canabinoide e pelo menos um terpeno, e método de tratamento, alívio ou redução de pelo menos um sintoma de ibd em pacientes deles necessitados
JP2021525709A (ja) 自閉症スペクトラム障害の治療のためのカンナビスベースの組成物
ES3039507T3 (en) Cannabidiol for treatment of anxiety in dogs
EP4175625A2 (en) Compositions comprising cannabidiol and flavanones
WO2019159176A1 (en) Compositions and methods for treatment of neurodegenerative diseases
Sirbu et al. Cannabinoids-a new therapeutic strategy in neurology
Gupta et al. Valbenazine for the treatment of adults with tardive dyskinesia
JP2011530543A (ja) 感覚欠損を治療するための組成物および方法
JP2024535871A (ja) アルツハイマー病による認知症を有する患者をｔｈｃとメラトニンとの組合せで処置するための組成物および方法
US20230338397A1 (en) Composition comprising cannabinoids, and/or terpens, and methods of using same
Mathew Essential oil-related brain disorders: an unexplored under-recognized conundrum
Mathew An Unexplored Under-recognized
WO2023215338A1 (en) Compositions and methods for treating cluster headache
JP6216913B1 (ja) 医薬組成物
CN118973563A (zh) 5-氨基-2,3-二氢-1,4-酞嗪二酮与富马酸酯的组合
Singha et al. Cannabis sativa a Promising Therapeutic Agent in Treatment of Various Health Associated Problem

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2806 DE 15-10-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.